US4158060A
Expired / Lapsed
US
⏱️ 0.0 years remaining
2-Methoxy-benzamide derivatives
Assignee: Synthelabo SA
•
Filing: 1976-12-10
•
Granted: 1979-06-12
•
Expires: 1996-12-10
Abstract
Abstract The invention provides novel 2-methoxy-benzamide derivatives of the formula: ##STR1## in which n is 1 or 2; R 1 represents a cycloalkyl-alkyl radical of formula: ##STR2## a phenylalkyl radical of formula ##STR3## (in which m is an integer from 2 to 5, A is a linear or branched alkylene chain of 1 to 4 carbon atoms, and R 4 is hydrogen, halogen, especially fluorine or chlorine, trifluoromethyl, or alkyl or alkoxy of 1 to 3 carbon atoms), CNCH 2 --CH 2 --, CH.tbd.C--CH 2 --, ##STR4## R 2 is either chlorine, SO 2 R 5 (in which R 5 is alkyl of 1 to 4 carbon atoms), or SO 2 NR 6 R 7 (in which, R 6 and R 7 , which are identical or different, represent, independently of one another, hydrogen or alkyl of 1 to 4 carbon atoms); and R 3 is hydrogen or alkyl of 1 to 4 carbon atoms; in the form of racemates or optical isomers, and their pharmaceutically acceptable acid addition salts, which are useful in the treatment of psychosomatic and psychotic disturbances.
Inventors
- 👤 Jean-Pierre Kaplan
- 👤 Bernard M. Raizon
- 👤 Daniel C. L. Obitz
- 👤 Philippe M. J. Manoury
- 👤 Henry Najer
- 👤 Maurice Jalfre
- 👤 Don P. R. L. Giudicelli
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-07 21:53
CPC Classifications
C; C07; C07D; C07D207/00; C07D207/02; C07D207/18; C07D207/22; C07D207/24; C07D207/26; C07D207/263; C07D207/27; C07D207/04; C07D207/08; C07D207/20; C07D211/00; C07D211/04; C07D211/06; C07D211/08; C07D211/18; C07D211/26; C07D211/68; C07D211/70; C07D211/72; C07D211/74; C07D211/76
Claims Analysis
Total Claims: 20
Claim 1
Independent Claim
87 words
A compound of the formula ##STR75## wherein A is a linear or branched alkylene chain of 1 to 4 carbon atoms; R 3 is hydrogen or alkyl of 1 to 4 carbon atoms; R 4 is hydrogen, halogen, trifluoromethyl, alkoxy of 1 to 3 carbon atoms or alkyl of 1 to 3 carbon atoms; and R 5 is alkyl of 1 to 4 carbon atoms in the form of a racemate or optical isomer, or a pharmaceutically acceptable acid addition salt of said racemate or optical isomer.
Claim 2
Dependent Claim
87 words
A compound of the formula ##STR75## wherein A is a linear or branched alkylene chain of 1 to 4 carbon atoms; R 3 is hydrogen or alkyl of 1 to 4 carbon atoms; R 4 is hydrogen, halogen, trifluoromethyl, alkoxy of 1 to 3 carbon atoms or alkyl of 1 to 3 carbon atoms; and R 5 is alkyl of 1 to 4 carbon atoms in the form of a racemate or optical isomer, or a pharmaceutically acceptable acid addition salt of said racemate or optical isomer.
Claim 3
Dependent Claim
12 words
A compound of claim 1, wherein R 3 is hydrogen or methyl.
Claim 4
Dependent Claim
15 words
A compound of claim 2, wherein A is --CH 2 -- or --CH(CH 3 )--.
Claim 5
Dependent Claim
11 words
A compound of claim 3, wherein A is --CH 2 --.
Claim 6
Dependent Claim
28 words
A compound of claim 4, wherein R 4 is hydrogen, chlorine, fluorine, trifluoromethyl, alkoxy of 1 to 3 carbon atoms or alkyl of 1 to 3 carbon atoms.
Claim 7
Dependent Claim
17 words
A compound of claim 5, wherein R 4 is chlorine or fluorine and R 3 is hydrogen.
Claim 8
Dependent Claim
16 words
A compound according to claim 1, which is N-[(1-p-fluorobenzyl-pyrrolidinyl-2)-methyl]-2-methoxy-5-methylsulphonyl-benzamide and its pharmaceutically acceptable acid addition salts.
Claim 9
Dependent Claim
34 words
A pharmaceutical agent capable of treating nervous and psychosomatic disorders which comprises an effective amount of the compound of claim 1 for treating said nervous and psychosomatic disorders and a compatible pharmaceutically acceptable carrier.
Claim 10
Dependent Claim
23 words
A method of combatting nervous and psychosomatic disorders in a patient which comprises administering to said patient said pharmaceutical agent of claim 8.
Claim 11
Dependent Claim
77 words
A compound of the formula ##STR76## wherein A is a linear or branched alkylene chain of 1 to 4 carbon atoms; R 3 is hydrogen or alkyl of 1 to 4 carbon atoms; and R 4 is hydrogen, halogen, trifluoromethyl, alkoxy of 1 to 3 carbon atoms or alkyl of 1 to 3 carbon atoms; in the form of a racemate or optical isomer, or a pharmaceutically acceptable acid addition salt of said racemate or optical isomer.
Claim 12
Dependent Claim
77 words
A compound of the formula ##STR76## wherein A is a linear or branched alkylene chain of 1 to 4 carbon atoms; R 3 is hydrogen or alkyl of 1 to 4 carbon atoms; and R 4 is hydrogen, halogen, trifluoromethyl, alkoxy of 1 to 3 carbon atoms or alkyl of 1 to 3 carbon atoms; in the form of a racemate or optical isomer, or a pharmaceutically acceptable acid addition salt of said racemate or optical isomer.
Claim 13
Dependent Claim
12 words
A compound of claim 10, wherein R 3 is hydrogen or methyl.
Claim 14
Dependent Claim
15 words
A compound of claim 11, wherein A is --CH 2 -- or --CH(CH 3 )--.
Claim 15
Dependent Claim
11 words
A compound of claim 12, wherein A is --CH 2 --.
Claim 16
Dependent Claim
28 words
A compound of claim 13, wherein R 4 is hydrogen, chlorine, fluorine, trifluoromethyl, alkoxy of 1 to 3 carbon atoms or alkyl or 1 to 3 carbon atoms.
Claim 17
Dependent Claim
17 words
A compound of claim 14, wherein R 4 is chlorine or fluorine and R 3 is hydrogen.
Claim 18
Dependent Claim
16 words
A compound according to claim 10, which is N-[(1-p-fluorobenzyl-pyrrolidinyl-2)-methyl]-2-methoxy-5-chloro-benzamide and its pharmaceutically acceptable acid addition salts.
Claim 19
Dependent Claim
33 words
A pharmaceutical agent capable of treating nervous and psychosomatic disorders which comprises effective amount of the compound of claim 10 for treating said nervous and psychosomatic disorders and a compatible pharmaceutically acceptable carrier.
Claim 20
Dependent Claim
23 words
A method of combatting nervous and psychosomatic disorders in a patient which comprises administering to said patient said pharmaceutical agent of claim 17.
References Cited (Backward Citations)
DD67123A
Cited
US3342826A
Cited
US3723416A
Cited
US3891671A
Cited
US3923829A
Cited
US3862139A
Cited
DE2442885A1
Cited
US3975434A
Cited
DE2452405A1
Cited
US4029673A
Cited
US4021567A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1982-06-11 | 1982-12-11 | 1983-06-12 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1986-06-11 | 1986-12-11 | 1987-06-12 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1990-06-11 | 1990-12-11 | 1991-06-12 | $7700.00 | Window Closed / Lapsed |